Pfizer Profit Margin

The latest profit margin for PFE.NE is 6.81% as of June 2026. That compares with 16.8% in the prior-year period — down 59.5% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Pfizer's historical trend and sector peers before judging valuation or financial health.

Over the past year, PFE.NE's profit margin moved from 16.8% to 6.81% — a 59.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pfizer's valuation or profitability profile.

Against Healthcare companies, PFE.NE currently prints 6.81% for profit margin, while the sector average sits near 9.48%. That is roughly 28.2% below the sector mean. Large gaps often invite a closer look at Pfizer's growth, margins, and balance sheet.

Profit Margin shows how effectively Pfizer converts resources into returns. At 6.81%, PFE.NE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 16.8% in the prior-year period — down 59.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PFE.NE's profit margin (6.81%), review year-over-year change from 16.8%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.